Clinical Trial: the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases

U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07339540) titled 'the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases' on Nov. 26, 2025.

Brief Summary: This study is designed as a single arm, open label, single center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetic or pharmacodynamic characteristics of the investigational drug V001-BCMA in autoimmune disease.

Study Start Date: Nov. 04, 2025

Study Type: INTERVENTIONAL

Condition: Recurrent or Refractory Systemic Lupus Erythematosus Recurrent or Refractory IgG4 Related Diseases Recurrent or Refractory Systemic Sclerosis Recurrent or Refractory Idiopathic Infl...